Randomized Trialhigh evidence
Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.
Lancet (London, England)·June 8, 2026·PMID 42259339
Why it mattersOrforglipron is an oral, non-peptide GLP-1 receptor agonist, offering a potential alternative to injectable GLP-1 therapies and oral SGLT2 inhibitors. Its superior glycemic efficacy over dapagliflozin, despite higher GI tolerability issues, may expand oral combination options for type 2 diabetes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled